Aviron


Jan 08, 02

12:49 ET Aviron Replies to Complete Response Letter

 
Nov 06, 01

07:31 ET Aviron Names Mike Makris Vice President, Controller

 
Oct 25, 01

16:06 ET Aviron Announces Third Quarter, Nine Month 2001 Results

 
Oct 19, 01

16:28 ET Aviron to Host Conference Call on Third Quarter 2001 Results

 
Sep 26, 01

19:49 ET Aviron Announces Management Appointments

 
Sep 07, 01

07:30 ET Aviron Names Luc Hermans Vice President & UK Site Director

 
Sep 03, 01

18:01 ET Aviron Receives Complete Response Letter Following FDA Review Of FluMist(TM) BLA

 
Aug 02, 01

17:09 ET Aviron Announces Second Quarter, First Half 2001 Results

 
Jul 31, 01

19:09 ET Aviron to Host Conference Call on Second Quarter 2001 Results

 
Jul 27, 01

18:24 ET Aviron to Host Conference Call

 
16:27 ET FDA Advisory Committee Evaluates FluMist(TM) Safety & Efficacy Data

 
Jul 26, 01

08:06 ET Trading Halted on Aviron Stock

 
Jun 26, 01

20:02 ET FDA Advisory Committee Scheduled to Review FluMist(TM) July 26-27

 
Jun 18, 01

09:00 ET Aviron Announces Redemption of 5 3/4 Percent Convertible Subordinated Notes Due 2005

 
May 21, 01

17:38 ET Aviron Elects Barbara Franklin to Board of Directors

 
Apr 25, 01

20:36 ET Aviron Announces First Quarter 2001 Results

 
Apr 23, 01

18:09 ET Aviron to Host Conference Call on First Quarter 2001 Results

 
Feb 02, 01

06:32 ET Aviron Prices Public Offerings of 4,000,000 Shares of Common Stock And $200 Million of 5 1/4 Percent Convertible Notes Due 2008

 
Jan 31, 01

18:45 ET Aviron Announces Fourth Quarter, Year End Results

 
Jan 29, 01

06:45 ET Aviron Announces $8 Million Financing

 
Jan 24, 01

08:45 ET Aviron Promotes Prasad to Senior Vice President, Technical Affairs

 
Jan 12, 01

09:03 ET Aviron Commences Public Offerings of 3,000,000 Shares of Common Stock And $150 Million of Convertible Notes

 
Jan 08, 01

22:27 ET Aviron Receives $10 Million Payment for Flumist(TM) Manufacturing

 
Dec 29, 00

16:05 ET FDA Accepts FluMist(TM) Biologics License Application (BLA) for Review

 
Dec 28, 00

19:14 ET Aviron Announces $8 Million Financing

 
Dec 18, 00

09:53 ET Aviron Announces Filing of Universal Shelf Registration Statement

 
Nov 29, 00

19:20 ET Aviron Announces $8 Million Financing

 
Oct 31, 00

16:22 ET Aviron Submits Biologics License Application for FluMist(TM)

    
Oct 26, 00

07:00 ET Aviron Announces Third Quarter, Nine Month 2000 Results

 
Oct 25, 00

16:38 ET Aviron Announces Initiation of Phase 2 Clinical Trial With Epstein-Barr Virus Vaccine

 
Oct 11, 00

07:02 ET Aviron Strengthens FluMist(TM) Commercial Infrastructure With Two Transactions In United Kingdom

 
Oct 03, 00

18:27 ET Aviron Announces $8 Million Financing

 
Sep 29, 00

08:35 ET Aviron Awarded Grant to Create Vaccine for Future Influenza Pandemics

 
Sep 11, 00

08:00 ET Aviron Names Dr. Harry Greenberg Chief Scientific Officer

 
Sep 06, 00

17:56 ET Aviron Announces $8 Million Financing

 
Aug 30, 00

08:01 ET Aviron Elects Douglas to Board of Directors

 
Aug 08, 00

17:16 ET Aviron Announces $8 Million Financing

 
Aug 07, 00

17:28 ET Aviron Names New Vice Presidents of Regulatory Affairs and Manufacturing

 
Jul 26, 00

20:17 ET Aviron Announces Second Quarter, First Half 2000 Results

 
Jul 11, 00

18:49 ET Aviron Announces $8 Million Financing

 
Jun 30, 00

07:00 ET Clinical Testing Begins With Aviron CMV Vaccine

 
Jun 23, 00

16:05 ET Aviron and NIH Extend FluMist Agreement

 
Jun 12, 00

18:38 ET Aviron Announces $8 Million Financing

 
May 12, 00

18:36 ET Aviron Announces $8 Million Financing

 
May 11, 00

21:05 ET Aviron Elects Mendelson to Board of Directors

 
20:52 ET Aviron Promotes Arcuri to Senior Vice President, Operations

 
Apr 27, 00

19:06 ET Aviron Announces First Quarter 2000 Results

 
Apr 14, 00

16:05 ET Aviron Names Friedman Vice President and General Counsel

 
Apr 13, 00

18:48 ET Aviron Announces $4 Million Financing

 
Apr 06, 00

15:23 ET Aviron Prices Follow-On Offering

 
Mar 08, 00

11:18 ET Aviron Announces Public Offering of 3,000,000 Shares of Common Stock

 
Mar 07, 00

20:38 ET Aviron Announces Update on BLA Submission Timing

 
Mar 06, 00

18:15 ET Aviron Adds Fenton and Hockmeyer to Board of Directors

 
Mar 02, 00

19:02 ET Aviron Announces Fourth Quarter, Year End Results

 
Feb 17, 00

16:05 ET Aviron Accelerates Issuance of Warrant to University of Michigan

 
Feb 03, 00

16:23 ET Aviron Announces $8 Million Financing

 
Jan 12, 00

16:05 ET Aviron Announces $48 Million Financing Commitment

 
Dec 16, 99

19:33 ET Aviron Announces $5.3 Million Financing

 
Dec 14, 99

20:22 ET Published Data Reports Aviron's FluMist(TM) Provided Protection Against Influenza

 
Dec 06, 99

00:01 ET Aviron Names New Chief Executive Officer

 
Nov 18, 99

12:23 ET Aviron Announces $6 Million Financing

 
Nov 14, 99

22:12 ET Aviron Announces Delay of BLA Submission

 
22:09 ET Aviron Announces Third Quarter, Nine Month Results

 
Sep 16, 99

07:30 ET Aviron Announces Filing of Shelf Registration Statement

 
Sep 01, 99

16:13 ET Aviron Names Bluth Senior Manager, Corporate Communications

 
Aug 11, 99

16:05 ET Aviron Announces Results of Phase 1 Clinical Trial for Epstein-Barr Virus Vaccine

 
Aug 05, 99

16:04 ET Aviron Announces Second Quarter, First Half Results

 
Jul 26, 99

16:05 ET Aviron Names VPs for New Positions in Manufacturing and Technical Affairs

 
Jul 13, 99

16:05 ET JAMA Publishes Study on the Results of Aviron's FluMist(TM) in Working Adults

 
Jul 12, 99

13:26 ET Aviron, Medeva Pharma Extend Manufacturing Collaboration

 
Jun 09, 99

06:30 ET Aviron Bridging Study Completed

 
May 03, 99

16:05 ET Aviron Announces First Quarter, 1999 Results

 
Mar 18, 99

09:00 ET Global Agreement Between Aviron and Wyeth on FluMist Effective as FTC Grants Early Termination Of Review

 
Mar 02, 99

11:00 ET Aviron Names Mocca VP Regulatory Affairs

 
Feb 17, 99

16:05 ET Aviron Announces FY 1998 Results

 
Jan 12, 99

16:51 ET Aviron Provides Additional Information About Global Collaboration on FluMist(TM) with Wyeth Lederle Vaccines

 
Dec 10, 98

16:05 ET Aviron Meets With FDA Regarding FluMist(TM) License Applications

 
Dec 05, 98

23:00 ET Preliminary Results of Aviron FluMist Studies Presented at International Influenza Symposium

 
Nov 09, 98

16:05 ET Aviron Announces Third Quarter, Nine Month Results

 
Oct 09, 98

16:15 ET Aviron Clarifies Study Results Reported by the Media

 
Sep 27, 98

11:30 ET New Data Presented at ICAAC Shows Aviron's FluMist(TM) Intranasal Influenza Vaccine Provided 86% Protection Against a Variant Strain Of Influenza in Children

 
Aug 31, 98

00:44 ET Aviron Receives Non-Filable Notification From FDA on FluMist;

 
Aug 19, 98

16:05 ET Becton Dickinson and Aviron Sign Joint Supply Agreement for FluMist(TM) Intranasal Influenza Vaccine Spray Device

 
Aug 12, 98

11:00 ET Aviron Names Vorheis VP Manufacturing

 
Aug 11, 98

08:45 ET Aviron Announces Second Quarter, First Half Results

 
Aug 06, 98

11:05 ET Aviron Announces Commencement of First Study to Assess Widespread Pediatric Influenza Vaccination

 
Aug 04, 98

11:00 ET Aviron Receives Small Business Innovation Research Grant for Development Of Cytomegalovirus Vaccine

 
Aug 03, 98

16:03 ET Aviron Announces Preliminary Results From a Year-Two Phase 3 Study Of FluMist(TM) in Children

 
Jul 01, 98

08:31 ET Aviron Announces Submission of a Product License Application For FluMist(TM) - The First Intranasal Influenza Vaccine

 
Jun 29, 98

12:27 ET Aviron CEO J. Leighton Read Named Life Sciences Entrepreneur of the Year

 
Jun 22, 98

16:15 ET Aviron, CSL Limited Sign Agreement on Licensing and Distribution Of FluMist(TM), Aviron's Intranasal Influenza Vaccine

 
Jun 18, 98

11:00 ET Aviron Names Christenson Director, Corporate Communications

 
Jun 15, 98

11:01 ET Aviron Names Olson Senior Vice President, Commercial Development

 
May 13, 98

17:00 ET New England Journal of Medicine Publishes Data Showing Aviron's FluMist(TM) Vaccine Is 93% Effective Against Influenza

 
May 11, 98

05:30 ET Aviron Announces First Quarter 1998 Results

 
Mar 17, 98

07:00 ET Aviron Announces Proposed $100 Million Convertible Note Offer

 
Feb 24, 98

08:05 ET Aviron Announces Positive Results of Consistency Lot Trial

 
Jan 30, 98

16:06 ET Aviron Announces Avian Influenza Vaccine Collaboration

 
Jan 09, 98

16:30 ET Aviron Announces Naming of New Chief Financial Officer

 
Dec 16, 97

17:00 ET Aviron Announces Update on Fall Clinical Program

 
Dec 15, 97

16:53 ET Aviron Announces Update on Fall Clinical Program

 
Dec 03, 97

16:27 ET Aviron Announces Commencement of Phase I Clinical Trial of Epstein-Barr Virus Vaccine

 
Oct 08, 97

16:00 ET Aviron Adopts Shareholder Rights Plan

 
Sep 17, 97

16:09 ET Aviron and Chiron Settle Litigation

 
Sep 15, 97

16:28 ET Aviron Appoints C. Jo White, M.D. as Senior Vice President, Medical Affairs

 
Jul 14, 97

15:16 ET Nasal Spray Flu Vaccine Proves Effective in Children in NIH Study

 
15:14 ET NIH Announcement of Pivotal Phase III Intranasal Influenza Vaccine Trial Success

 
May 15, 97

13:07 ET Aviron and Medeva Announce Manufacturing Agreement

 
Apr 01, 97

11:45 ET Aviron Announces $15 Million in Private Financing

 
Mar 10, 97

16:32 ET Aviron Announces Third Quarter 1997 Unblinding of Phase III Influenza Vaccine Clinical Results

 
Sep 18, 96

10:42 ET Aviron Announces Gene Therapy Alliance With NeuroVir

 
Aug 26, 96

08:04 ET Aviron Initiates Pivotal Phase III Trial of Intranasal Influenza Vaccine

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.